All articles by Mrinmoyee Hazarika

  1. Mirati Therapeutics doses first patient in MRTX849 trial

    Mirati Therapeutics has dosed the first patient in a Phase I/II clinical trial evaluating MRTX849 as a single agent for…
    Read More…

    17 Jan
  2. UNS reports positive results from Alzheimer’s vaccine trial

    United Neuroscience (UNS) has reported positive top-line results from its Phase IIa clinical trial evaluating UB-311 in patients with Alzheimer’s…
    Read More…

    17 Jan
  3. Aivita Biomedical secures US FDA approval for melanoma drug trial

    Aivita Biomedical has secured approval from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application…
    Read More…

    17 Jan
  4. ASLAN reports negative data from trial of gastric cancer drug

    ASLAN Pharmaceuticals has reported negative results from a Phase II trial comparing varlitinib plus mFOLFOX6 to placebo plus mFOLFOX6first in…
    Read More…

    15 Jan
  5. Daiichi Sankyo doses first patient in DESTINY-Breast04 trial

    Daiichi Sankyo Company has dosed the first patient in the Phase III DESTINY-Breast04 trial that aims to investigate [fam-] trastuzumab…
    Read More…

    15 Jan
  6. miRagen reports positive Phase I cobomarsen data for CTCL and ATLL

    miRagen Therapeutics has reported positive updated data from a Phase I trial assessing the safety, tolerability and efficacy of cobomarsen…
    Read More…

    14 Jan
  7. Researchers report positive results from motor neurone disease trial

    A team of researchers led by Australia’s Macquarie University professor Dominic Rowe and Calvary Health Care Bethlehem associate professor Susan…
    Read More…

    14 Jan
  8. Tolero doses first patient in Phase I TP-1287 trial

    Tolero Pharmaceuticals has dosed the first patient in a Phase I trial assessing TP-1287 for the treatment of patients with…
    Read More…

    14 Jan
  9. Vaccine for pregnancy malaria passes trial in humans

    A team of researchers from University of Copenhagen in Denmark has reported positive results from a Phase I clinical trial…
    Read More…

    11 Jan
  10. Rafael starts trial of CPI-613 and mFFX for pancreatic cancer

    Rafael Pharmaceuticals has commenced a Phase II trial to investigate the efficacy and safety of CPI-613 in combination with modified…
    Read More…

    11 Jan

Go Top